88 related articles for article (PubMed ID: 17659482)
1. A historical perspective and recent advances in prostamide research and therapeutics.
Burk RM; Woodward DF
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):413-21. PubMed ID: 17659482
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in prostaglandin F2α ethanolamide (prostamide F2α) research and therapeutics.
Woodward DF; Wang JW; Poloso NJ
Pharmacol Rev; 2013; 65(4):1135-47. PubMed ID: 23893067
[TBL] [Abstract][Full Text] [Related]
3. Prostamides (prostaglandin-ethanolamides) and their pharmacology.
Woodward DF; Liang Y; Krauss AH
Br J Pharmacol; 2008 Feb; 153(3):410-9. PubMed ID: 17721551
[TBL] [Abstract][Full Text] [Related]
4. Bimatoprost: a novel antiglaucoma agent.
Woodward DF; Phelps RL; Krauss AH; Weber A; Short B; Chen J; Liang Y; Wheeler LA
Cardiovasc Drug Rev; 2004; 22(2):103-20. PubMed ID: 15179448
[TBL] [Abstract][Full Text] [Related]
5. Enzymatic formation of prostamide F2alpha from anandamide involves a newly identified intermediate metabolite, prostamide H2.
Yang W; Ni J; Woodward DF; Tang-Liu DD; Ling KH
J Lipid Res; 2005 Dec; 46(12):2745-51. PubMed ID: 16150817
[TBL] [Abstract][Full Text] [Related]
6. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence.
Krauss AH; Woodward DF
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S5-11. PubMed ID: 15016556
[TBL] [Abstract][Full Text] [Related]
7. The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products.
Woodward DF; Carling RW; Cornell CL; Fliri HG; Martos JL; Pettit SN; Liang Y; Wang JW
Pharmacol Ther; 2008 Oct; 120(1):71-80. PubMed ID: 18700152
[TBL] [Abstract][Full Text] [Related]
8. Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides.
Smid SD
Clin Ophthalmol; 2009; 3():663-70. PubMed ID: 20054414
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024).
Woodward DF; Krauss AH; Chen J; Liang Y; Li C; Protzman CE; Bogardus A; Chen R; Kedzie KM; Krauss HA; Gil DW; Kharlamb A; Wheeler LA; Babusis D; Welty D; Tang-Liu DD; Cherukury M; Andrews SW; Burk RM; Garst ME
J Pharmacol Exp Ther; 2003 May; 305(2):772-85. PubMed ID: 12606640
[TBL] [Abstract][Full Text] [Related]
10. The pharmacology of bimatoprost (Lumigan).
Woodward DF; Krauss AH; Chen J; Lai RK; Spada CS; Burk RM; Andrews SW; Shi L; Liang Y; Kedzie KM; Chen R; Gil DW; Kharlamb A; Archeampong A; Ling J; Madhu C; Ni J; Rix P; Usansky J; Usansky H; Weber A; Welty D; Yang W; Tang-Liu DD; Garst ME; Brar B; Wheeler LA; Kaplan LJ
Surv Ophthalmol; 2001 May; 45 Suppl 4():S337-45. PubMed ID: 11434936
[TBL] [Abstract][Full Text] [Related]
11. Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris.
Woodward DF; Krauss AH; Wang JW; Protzman CE; Nieves AL; Liang Y; Donde Y; Burk RM; Landsverk K; Struble C
Br J Pharmacol; 2007 Feb; 150(3):342-52. PubMed ID: 17179945
[TBL] [Abstract][Full Text] [Related]
12. Bimatoprost and prostaglandin F(2 alpha) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells.
Spada CS; Krauss AH; Woodward DF; Chen J; Protzman CE; Nieves AL; Wheeler LA; Scott DF; Sachs G
Exp Eye Res; 2005 Jan; 80(1):135-45. PubMed ID: 15652534
[TBL] [Abstract][Full Text] [Related]
13. Identification of prostamides, fatty acyl ethanolamines, and their biosynthetic precursors in rabbit cornea.
Urquhart P; Wang J; Woodward DF; Nicolaou A
J Lipid Res; 2015 Aug; 56(8):1419-33. PubMed ID: 26031663
[TBL] [Abstract][Full Text] [Related]
14. Anandamide-derived prostamide F2α negatively regulates adipogenesis.
Silvestri C; Martella A; Poloso NJ; Piscitelli F; Capasso R; Izzo A; Woodward DF; Di Marzo V
J Biol Chem; 2013 Aug; 288(32):23307-21. PubMed ID: 23801328
[TBL] [Abstract][Full Text] [Related]
15. Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors.
Chen J; Lu RT; Lai R; Dinh T; Paul D; Venadas S; Wheeler LA
Curr Eye Res; 2009 Mar; 34(3):184-95. PubMed ID: 19274525
[TBL] [Abstract][Full Text] [Related]
16. The inflow and outflow of anti-glaucoma drugs.
Woodward DF; Gil DW
Trends Pharmacol Sci; 2004 May; 25(5):238-41. PubMed ID: 15120486
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
Feng Z; Hellberg MR; Sharif NA; McLaughlin MA; Williams GW; Scott D; Wallace T
Bioorg Med Chem; 2009 Jan; 17(2):576-84. PubMed ID: 19101156
[TBL] [Abstract][Full Text] [Related]
18. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences.
Bean GW; Camras CB
Surv Ophthalmol; 2008 Nov; 53 Suppl1():S69-84. PubMed ID: 19038626
[TBL] [Abstract][Full Text] [Related]
19. Flare-up rates with bimatoprost therapy in uveitic glaucoma.
Fortuna E; Cervantes-Castañeda RA; Bhat P; Doctor P; Foster CS
Am J Ophthalmol; 2008 Dec; 146(6):876-82. PubMed ID: 19027422
[TBL] [Abstract][Full Text] [Related]
20. Prostaglandin ethanolamides attenuate damage in a human explant colitis model.
Nicotra LL; Vu M; Harvey BS; Smid SD
Prostaglandins Other Lipid Mediat; 2013 Jan; 100-101():22-9. PubMed ID: 23380599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
